

**Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy:  
Findings from a Retrospective US Claims Database Analysis**

Walter Toro<sup>1</sup>; Min Yang<sup>2</sup>; Mihaela Georgieva<sup>2</sup>; Wei Song<sup>2</sup>; Anish Patel<sup>1</sup>; Anya (Xinyi) Jiang<sup>2</sup>;  
Angela Zhao<sup>2</sup>; Nicole LaMarca<sup>1</sup>; Omar Dabbous<sup>1</sup>

<sup>1</sup>Novartis Gene Therapies, Inc., Bannockburn, Illinois, USA; <sup>2</sup>Analysis Group, Inc., Boston,  
Massachusetts, USA

**Corresponding author:**

Walter Toro, MD, PhD

Novartis Gene Therapies, Inc.

2275 Half Day Road, Suite 200

Bannockburn, IL 60015, USA

E-mail: [walter.toro\\_jimenez@novartis.com](mailto:walter.toro_jimenez@novartis.com)

## Supplemental Material

Table S1. List of codes to identify patients treated with onasemnogene abeparvovec, nusinersen, or risdiplam.

Treatment	Code type	Codes
Onasemnogene abeparvovec	NDC	71894-0110-01
		71894-0115-01
		71894-0120-02
		71894-0121-03
		71894-0122-03
		71894-0123-03
		71894-0124-04
		71894-0125-04
		71894-0126-04
		71894-0127-05
		71894-0128-05
		71894-0129-05
	71894-0130-06	
	HCPCS	J3399
Nusinersen	NDC	64406-058-01
		71860-396-01
	HCPCS	C9489
		J2326
Risdiplam	NDC	50242-0175-05
		50242-0175-07

**Abbreviations:** HCPCS: Healthcare Common Procedure Coding System; NDC: National Drug Code.

Table S2. List of codes to identify SMA-related comorbidities.

<b>Comorbidities</b>	<b>ICD-10-CM codes</b>
Muscle weakness (generalized)	M62.81
Dyspnea and respiratory anomalies	R06.x
Failure to thrive	P92.6, R62.51, R62.7
Dysphagia, unspecified	R13.10
Feeding difficulties and mismanagement	R63.3
Acute respiratory failure	J96.0x, J96.2x
Scoliosis	M41.x

**Abbreviations:** ICD-10-CM: International Classification of Diseases, Tenth Revision, Clinical Modification.